Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 8;10(2):ofad067.
doi: 10.1093/ofid/ofad067. eCollection 2023 Feb.

Non-AIDS-Defining Events in Human Immunodeficiency Virus Controllers Versus Antiretroviral Therapy-Controlled Patients: A Cohort Collaboration From the French National Agency for Research on AIDS CO21 (CODEX) and CO06 (PRIMO) Cohorts

Carmelite Manto  1   2 , Alicia Castro-Gordon  3 , Cécile Goujard  1   3 , Laurence Meyer  1   4 , Olivier Lambotte  3   5 , Asma Essat  1   4 , Arnoo Shaiykova  1 , Faroudy Boufassa  1 , Nicolas Noël  3   5
Affiliations

Non-AIDS-Defining Events in Human Immunodeficiency Virus Controllers Versus Antiretroviral Therapy-Controlled Patients: A Cohort Collaboration From the French National Agency for Research on AIDS CO21 (CODEX) and CO06 (PRIMO) Cohorts

Carmelite Manto et al. Open Forum Infect Dis. .

Abstract

Background: Low-grade chronic inflammation may persist in spontaneous human immunodeficiency virus controllers (HICs), leading to non-AIDS-defining events (nADEs).

Methods: Two hundred twenty-seven antiretroviral therapy (ART)-naive HICs (known human immunodeficiency virus type 1 [HIV-1] infection ≥5 years and at least 5 consecutive viral loads [VLs] <400 HIV RNA copies/mL) were compared with 328 patients who initiated ART ≤1 month after primary HIV infection diagnosis and had undetectable VL within 12 months following ART initiation for at least 5 years. Incidence rates of first nADEs were compared between HICs and ART-treated patients. Determinants of nADEs were assessed by using Cox regression models.

Results: All-cause nADEs incidence rates were 7.8 (95% confidence interval [CI], 5.9-9.6) and 5.2 (95% CI, 3.9-6.4) per 100 person-months among HICs and ART patients, respectively (incidence rate ratio [IRR], 1.5 [95% CI, 1.1-2.2]; adjusted IRR, 1.93 [95% CI, 1.16-3.20]). After adjustment for the cohort, demographic, and immunological characteristics, the only other factor associated with all-cause nADE occurrence was age ≥43 (vs <43) years at the beginning of viral control (IRR, 1.69 [95% CI, 1.11-2.56]). The most frequent events observed in the 2 cohorts were non-AIDS-related benign infections (54.6% and 32.9% of all nADEs, respectively, for HICs and ART patients). No differences in cardiovascular or psychiatric events were observed.

Conclusions: HICs experienced 2 times more nADEs than virologically suppressed patients on ART, mainly non-AIDS-related benign infections. Older age was associated with nADE occurrence, independent of immune or virologic parameters. These results do not argue in favor of expanding the ART indication for HICs but rather a case-by-case approach considering clinical outcomes such as nADEs besides immune activation.

Keywords: ART; HIV; controllers; non-AIDS-defining events; primary infection.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. N. N. has received speaker fees from Takeda, Novartis, and Sanofi, outside the submitted work. O. L. received expert testimony and/or consultancy fees from BMS France, MSD, AstraZeneca and Janssen, and grants from Gilead, outside of the submitted work. All other authors report no potential conflicts.

Figures

Figure 1.
Figure 1.
Distribution of specific-cause non-AIDS-defining events among all non-AIDS-defining events, in human immunodeficiency virus controller (HIC) and antiretroviral therapy (ART) patient groups.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Baker JV, Neuhaus J, Duprez D, et al. . Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr 2011; 56:36–43. - PMC - PubMed
    1. Sereti I, Krebs SJ, Phanuphak N, et al. . Persistent, albeit reduced, chronic inflammation in persons starting antiretroviral therapy in acute HIV infection. Clin Infect Dis 2017; 64:124–31. - PMC - PubMed
    1. INSIGHT START Study Group; Lundgren JD, Babiker AG, et al. . Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015; 373:795–807. - PMC - PubMed
    1. Mussini C, Lorenzini P, Cozzi-Lepri A, et al. . CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. Lancet HIV 2015; 2:e98–106. - PubMed
    1. Méndez-Lagares G, Romero-Sánchez MC, Ruiz-Mateos E, et al. . Long-term suppressive combined antiretroviral treatment does not normalize the serum level of soluble CD14. J Infect Dis 2013; 207:1221–5. - PubMed